Summary
Since 1980, we have observed an increased incidence of otitis media caused by Branhamella catarrhalis. The outcome of therapy of acute otitis media caused by this organism has been studied in a number of randomised clinical trials. 75% of isolates produced β-lactamase. Failure to sterilise B. catarrhalis-infected middle ear exudates occurred in 3 of 11 patients treated with amoxycillin or bacampicillin, 2 of 19 treated with cefaclor, but in no patients treated with co-trimoxazole (n = 10) or amoxycillin-clavulanic acid (Augmentin), [n = 9]. All treatment failures were associated with β-lactamase-producing strains of B. catarrhalis.
The emergence of antibiotic-resistant strains of B. catarrhalis in acute otitis media indicates the need for a re-evaluation of initial antibiotic therapy of this infection. This may be particularly true for areas where there is a high incidence of strains which elaborate β-lactamase.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Johnsson J, Brorson JE. Influence of beta-lactamase-producing strains of Branhamella catarrhalis and Haemophilus influenzae on certain beta-lactam antibiotics. Journal of Antimicrobial Chemotherapy 12: 269–271, 1983
Johnson MA, Drew WL, Roberts M. Branhamella (Neisseria) catarrhalis — a lower respiratory tract pathogen? Journal of Clinical Microbiology 13: 1066–1069, 1981
Kovatch AL, Wald ER, Michaels RH. Beta-lactamase-producing Branhamella catarrhalis causing otitis media in children. Journal of Pediatrics 102: 261–264, 1983
Leinonen M, Luotonen J, Herva E, Valkonen K, Makela PH. Preliminary serologic evidence for a pathogenic role of Branhamella catarrhalis. Journal of Infectious Diseases 144: 570–574, 1981
Malmvall BE, Brorsson JE, Johnsson J. In vitro sensitivity to penicillin V, ampicillin and azidocillin and beta-lactamase production in Branhamella catarrhalis. Journal of Antimicrobial Chemotherapy 3: 374–378, 1977
Marchant CD, Shurin PA, Turcyzk VA, Feinstein JC, Johnson CE et al. A randomized controlled trial of cefaclor compared with trimethoprim-sulfamethoxazole for treatment of acute otitis media. Journal of Pediatrics 105: 633–638, 1984a
Marchant CD, Shurin PA, Wiltshire JC, Johnson CE, Turcyzk VA, et al. Twice daily antimicrobial therapy for acute otitis media. In Lim DJ (Ed.) Recent advances in otitis media with effusion, pp. P, BC Decker, Philadelphia, 1984b
Ninane G, Joly J, Kraytman M. Bronchopulmonary infection due to Branhamella catarrhalis; 11 cases assessed by transtracheal puncture. British Medical Journal 1: 276–278, 1978
O’Callaghan CH, Morris A, Kirby SM, Shingler AH. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrobial Agents and Chemotherapy 1: 283–288, 1972
Shurin PA, Kim CH, Fulton D, Marchant CD. Susceptibility of beta-lactamase-producing strains of Branhamella catarrhalis to selected, orally administered antimicrobial agents. In Lim DJ (Ed.) Recent advances in otitis media with effusion, pp. 283–285, BC Decker, Philadelphia, 1984
Shurin PA, Marchant CD, Kim CH, Van Hare GF, Johnson CE, et al. Emergence of beta-lactamase-producing strains of Branhamella catarrhalis as important agents of acute otitis media. Pediatric Infectious Disease 2: 34–38, 1983
Slevin NJ, Aitken J, Thornley PE. Clinical and microbiological features of Branhamella catarrhalis bronchopulmonary infections. Lancet 1: 782–783, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shurin, P.A., Van Hare, G.F. Therapy of Acute Otitis Media Caused by Branhamella catarrhalis . Drugs 31 (Suppl 3), 122–124 (1986). https://doi.org/10.2165/00003495-198600313-00027
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198600313-00027